MSLN-targeting bispecific t-cell engaging antibody, MG1122, for treatment of solid tumors.

e14500Background: Engaging T cells to attack tumors is a new class of immunotherapy. Tumor-specific T cell-engaging antibodies have an ability to redirect and activate T cells to target tumor cells...